Liver three-dimensional cellular models for high-throughput chemical testing.

Area of Science:

• Hepatotoxicity and Drug Development
• In Vitro Toxicology Models
• Liver Cell Culture Systems

Background:

• Drug-induced hepatotoxicity is a major reason for drug withdrawal.
• Current in vitro models (monolayer hepatocytes, HepG2, HepaRG) have limitations in mimicking in vivo metabolic competence for chronic toxicity testing.
• There is a need for more predictive liver models for drug safety assessment.

Purpose of the Study:

• To review the development of three-dimensional (3D) liver models for drug and chemical toxicity testing.
• To discuss the advantages and limitations of 3D liver models in high-throughput screening (HTS).
• To highlight the potential of 3D models in improving early-stage liver toxicity testing.

Main Methods:

• Review of current literature on the development and application of 3D liver models.
• Comparison of 3D liver models with traditional 2D cell culture systems (monolayer hepatocytes, HepG2, HepaRG).
• Evaluation of the recapitulation of in vivo liver function and metabolic capacity by 3D models.

Main Results:

• 3D liver models demonstrate enhanced recapitulation of normal liver function and metabolic capacity compared to 2D models.
• These models show potential for more accurate prediction of drug-induced liver injury.
• 3D liver models offer advantages for both short-term and potentially long-term toxicological assessments.

Conclusions:

• 3D liver models represent a significant advancement over traditional 2D systems for in vitro drug toxicity screening.
• Their improved physiological relevance makes them valuable tools for high-throughput screening in drug discovery.
• Further development and validation of 3D liver models are crucial for enhancing drug safety and reducing market withdrawals due to hepatotoxicity.